On our previous post we wrote on 5 May: Clinicians are now able to request whole genome sequencing (WGS) at the North West NHS Genomic Laboratory Hub for eligible patients with CUP in their care. This is a very significant step forward and excellent news. We are trying to find out from the NHS National Genomic Medicine Service whether WGS in
Read more
Clinicians are now able to request whole genome sequencing (WGS) at the North West NHS Genomic Laboratory Hub for eligible patients with CUP in their care. This is a very significant step forward and excellent news. We are trying to find out from the NHS National Genomic Medicine Service whether WGS in tissue extends to other regions.
NICE have responded to our request to establish the status of the review of CG104 – Metastatic Malignant Disease of Unknown Primary which had been scheduled pre-Pandemic. They have advised that the work has not yet started and they do not know when it will start.
The NHS have released a progress check against the NHS Long Term Plan commitments for cancer. There are two targets of particular interest to us: (1) the roll-out of RDCs and (2) genomic testing for patients who are newly diagnosed with cancer. Roll-out of Rapid Diagnostic Centres In 2019 every Cancer Alliance set up its first RDC pathway, based on
Read more
NCRI MUO/CUP Group webinar yesterday (6 May 2021) – Cancers of unknown primary – challenges and opportunities To watch the video on-demand, click here
On 29 April we sponsored a webinar, run by SBK, entitled ‘Enhancing Referral and Management of MUO/CUP Patients’ The webinar was led by Dr Sarah Ngan of GSTT and it can be viewed here.
CUP molecular tumour board – one day virtual event Registration: https://ti.to/gw/cup-symposium-2021
Our friends (see below) in Australia have expanded from the SUPER trial to SUPER-NEXT with funding from the Australian Federal Government. SUPER-NEXT uses state-of-the-art genomics approaches to interrogate the molecular landscape of CUPs. These studies aim to help resolve the cancer tissues of origin, as well as identify potential targeted treatment approaches, providing valuable new information to clinicians to help
Read more
We have been supportive of the concept of RDCs to speed diagnosis for people without obvious primary symptoms. As at Oct 2020 a report from NHS England shows: 34 RDCs are currently live, and a further 60 are in development. In July (most recent available data) RDCs received nearly 900 referrals and diagnosed over 130 cancers. 82% of live pathways
Read more
The 2020/2021 National Genomic Test Directory for cancer specifies the genomic tests commissioned by the NHS in England for cancer, the technology by which they are available, and the patients who will be eligible to access to a test. National Genomic test directory for cancer can be found here. It is then necessary to open an Excel spreadsheet and CUP
Read more